Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Non-transduced NK cells are natural killer cells that have not undergone genetic modification through viral or non-viral transduction methods. NK cells are a subset of large granular lymphocytes involved in the innate immune response, capable of killing tumor cells and virus-infected cells without prior sensitization. Their mechanism of action is primarily direct cytotoxicity via release of perforin and granzymes, induction of apoptosis through death receptor pathways (e.g., TRAIL/TRAIL-R, Fas/FasL), and antibody-dependent cellular cytotoxicity (ADCC) mediated by the CD16 (FcγRIII) receptor. These cells are regulated by a balance of activating and inhibitory surface receptors. In clinical applications, non-transduced NK cells are used in cell therapy approaches for certain cancers and viral infections, serving as a baseline for comparison to genetically modified (e.g., CAR-NK) cells[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on non-transduced NK cells.